Navigation Links
Cepheid Reports Second Quarter Revenue of $42.1 Million
Date:7/24/2008

assets (241) (122) (482) (297)

Non-GAAP measure of cost of product

sales $22,382 $13,615 $44,777 $26,987

Gross margin on product sales per GAAP 41% 41% 43% 39%

Gross margin on product sales per

Non-GAAP 43% 42% 45% 41%

Research and development $10,964 $7,439 $20,862 $14,361

Amortization of purchased

intangible assets (24) (24) (48) (48)

Stock compensation expense (1,414) (1,047) (2,677) (1,791)

Non-GAAP measure of cost of research

and development $9,526 $6,368 $18,137 $12,522

Sales and marketing $7,434 $5,067 $14,375 $9,560

Amortization of purchased

intangible assets (21) (18) (42) (23)

Stock compensation expense (909) (424) (1,754) (795)

Non-GAAP measure of cost of sales

and marketing $6,504 $4,625 $12,579 $8,742

General and administrative $5,518 $4,038 $10,265 $7,973

Stock compensation expense (1,137) (791) (1,940) (1,411)

Non-GAAP measure of cost of

general and administrative $4,381 $3,247 $8,325 $6,562

Income (Loss) from Operations $(7,513) $(5,981) $(10,985) $(13,161)

Stock compensation expense 3,707 2,298 6,968 4,299

Amortization of acquired inventory

step-up in basis - 106 - 170

Amortization of purchased

intangible assets 286 164 572 368

Non-GAAP measure of Income (Loss)

from Operations $(3,520) $(3,413) $(3,445) $(8,324)

Net
'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
9. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
10. Cepheid Reports Fourth Quarter and Full Year 2007 Results
11. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Potential new heart attack biomarker uncovered 2Successful stem cell therapy for treatment of eye disease 2IGC scientist receives prestigious EMBO installation grant 2Orphanage Receives Nearly 241 Million from Private Donor 53804 1Orphanage Receives Nearly 241 Million from Private Donor 53804 2Orphanage Receives Nearly 241 Million from Private Donor 53804 3SDSU 26apos 3Bs Process Improvement Programs Help Businesses Achieve Bottom Line Results 53801 1SDSU 26apos 3Bs Process Improvement Programs Help Businesses Achieve Bottom Line Results 53801 2SDSU 26apos 3Bs Process Improvement Programs Help Businesses Achieve Bottom Line Results 53801 3Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 1Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 2Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 3Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 4Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 5Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 6Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 7